- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06561685
Un estudio de LY4050784 en participantes con tumores sólidos avanzados o metastásicos
Un estudio multicéntrico de etiqueta abierta de LY4050784, un inhibidor selectivo de SMARCA2/BRM, en neoplasias malignas de tumores sólidos avanzados con alteraciones de SMARCA4/BRG1
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Charite-Universitatsmedizin Berlin
-
Essen, Alemania, 45147
- Universitaetsklinikum Essen
-
Frankfurt am Main, Alemania, 60488
- Krankenhaus Nordwest
-
-
-
-
-
Ilsandong-gu, Corea del Sur, 10408
- National Cancer Center
-
Seoul, Corea del Sur, 03722
- Severance Hospital, Yonsei University Health System
-
Suwon, Corea del Sur, 16247
- The Catholic University of Korea, St. Vincent's Hospital
-
-
-
-
-
Barcelona, España, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, España, 28040
- South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
-
-
-
-
California
-
Santa Monica, California, Estados Unidos, 90404
- UCLA
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Health Hospital
-
Denver, Colorado, Estados Unidos, 80218
- Sarah Cannon Research Institute at HealthOne
-
-
Florida
-
Lake Mary, Florida, Estados Unidos, 32746
- Florida Cancer Specialists ORLANDO/DDU
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
-
Illinois
-
New Lenox, Illinois, Estados Unidos, 60451
- University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Hospital
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Estados Unidos, 37232-6307
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, Estados Unidos, 37203
- SCRI Oncology Partners
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030-4009
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- USO-Virginia Cancer Specialists, PC
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
-
-
-
Bordeaux, Francia, 33 076
- Institut Bergonie
-
Paris, Francia, 75248
- Institut Curie
-
Villejuif, Francia, 94800
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
-
-
-
-
-
Chūōku, Japón, 104-0045
- National Cancer Center Hospital
-
Kashiwa, Japón, 277-8577
- National Cancer Center Hospital East
-
Kōtō City, Japón, 135-8550
- The Cancer Institute Hospital of JFCR
-
Nagaizumi-cho,Sunto-gun, Japón, 411-8777
- Shizuoka Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:
- Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)
- Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
-
Prior Systemic Therapy Criteria:
- Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.
- Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.
- Phase 1b expansion (Part C): Participants may be treatment naïve or have received therapy for advanced or metastatic disease
-
Measurability of disease
- Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
- Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Participants with known or likely loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations
- Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
- Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement
- Participants with history of increased risk of prolonged QT or significant arrythmia
- Significant cardiovascular disease
- Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment
- Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention
- Participants with history of active autoimmune diseases, history of allogenic stem cell/organ transplant or compromised immune system within past 2 years (Part C only)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: LY4050784 (Phase 1a - Dose Escalation)
Escalating doses of LY4050784 administered orally. |
Oral |
|
Experimental: LY4050784 (Phase 1b - Dose Optimization/Part A)
Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally. |
Oral |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part B)
LY4050784 administered orally. |
Oral |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1
LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a
LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b
LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
Number of participants with dose-limiting toxicities (DLTs) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Para evaluar las propiedades PK de LY4050784 en cohortes combinadas: concentración máxima (CMAX) PK: CMAX de LY4050784
Periodo de tiempo: Ciclo 1 (día 8)
|
Ciclo 1 (día 8)
|
|
|
Para evaluar las propiedades PK de LY4050784 en cohortes combinadas: tiempo de concentración máxima (Tmax) PK: Tmax de LY4050784
Periodo de tiempo: Ciclo 1 (día 8)
|
Ciclo 1 (día 8)
|
|
|
Para evaluar las propiedades PK de LY4050784 en cohortes combinadas: área bajo la curva de concentración versus tiempo (AUC)
Periodo de tiempo: Ciclo 1 (día 8)
|
Ciclo 1 (día 8)
|
|
|
To characterize the pharmacokinetics (PK) properties of LY4050784: Maximum Concentration (Cmax)
Periodo de tiempo: Cycle 1 (Day 8)
|
PK: Cmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Time to Maximum Concentration (Tmax)
Periodo de tiempo: Cycle 1 (Day 8)
|
PK: Tmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Area under the concentration versus time curve (AUC)
Periodo de tiempo: Cycle 1 (Day 8)
|
PK: AUC of LY4050784 |
Cycle 1 (Day 8)
|
|
Phase Ia: To evaluate the preliminary antitumor activity of LY4050784: Overall response rate (ORR)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Duration of response (DOR)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
DOR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Time to response (TTR)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
TTR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Disease control rate (DCR)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
DCR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Progression free survival (PFS)
Periodo de tiempo: Up to Approximately 48 Months or 4 Years
|
PFS per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Enfermedades pulmonares
- Neoplasias Glandulares y Epiteliales
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Procesos Neoplásicos
- Carcinoma
- Neoplasias De Células Escamosas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Condiciones Patológicas, Signos y Síntomas
- Neoplasias Pulmonares
- Carcinoma De Células Escamosas
- Metástasis de neoplasias
- Carcinoma de pulmón de células no pequeñas
- Adenocarcinoma
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Complejos de coordinación
- Guanina
- Hipoxantino
- Purinones
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Taxaides
- Ciclodecanos
- Diterpenos
- Economía y organizaciones de la atención médica
- Compuestos de platino
- Ciencias económicas
- Pemetrexed
- Carboplatino
- Paclitaxel
- Cisplatino
- pembrolizumab
- Impuestos
Otros números de identificación del estudio
- 27191
- J5M-OX-JOXA (Otro identificador: Eli Lilly and Company)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .